PMID- 25308927
OWN - NLM
STAT- MEDLINE
DCOM- 20150914
LR  - 20150106
IS  - 1708-8305 (Electronic)
IS  - 1195-1982 (Linking)
VI  - 22
IP  - 1
DP  - 2015 Jan-Feb
TI  - Safety and immunogenicity of typhoid fever and yellow fever vaccines when 
      administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate 
      vaccine in healthy adults.
PG  - 48-56
LID - 10.1111/jtm.12164 [doi]
AB  - BACKGROUND: Compact and short pre-travel immunization schedules, which include 
      several vaccinations in a single visit, are desirable for many travelers. 
      However, concomitant vaccination could potentially compromise immunogenicity 
      and/or safety of the individual vaccines and, therefore, possible vaccine 
      interferences should be carefully assessed. This article discusses the 
      immunogenicity and safety of travel vaccines for typhoid fever (TF) and yellow 
      fever (YF), when administered with or without a quadrivalent meningococcal 
      glycoconjugate ACWY-CRM vaccine (MenACWY-CRM). METHODS: Healthy adults 
      (18-</=60 years) were randomized to one of three vaccine regimens: 
      TF + YF + MenACWY-CRM (group I; n = 100), TF + YF (group II; n = 101), or 
      MenACWY-CRM (group III; n = 100). Immunogenicity at baseline and 4 weeks 
      post-vaccination (day 29) was assessed by serum bactericidal assay using human 
      complement (hSBA), enzyme-linked immunosorbent assay (ELISA), or a neutralization 
      test. Adverse events (AEs) and serious adverse events (SAEs) were collected 
      throughout the study period. RESULTS: Non-inferiority of post-vaccination 
      geometric mean concentrations (GMCs) and geometric mean titers (GMTs) was 
      established for TF and YF vaccines, respectively, when given concomitantly with 
      MenACWY-CRM vaccine versus when given alone. The percentages of subjects with 
      seroprotective neutralizing titers against YF on day 29 were similar in groups I 
      and II. The antibody responses to meningococcal serogroups A, C, W-135, and Y 
      were within the same range when MenACWY-CRM was given separately or together with 
      TF and YF vaccines. The percentage of subjects reporting AEs was the same for TF 
      and YF vaccines with or without MenACWY-CRM vaccine. There were no reports of 
      SAEs or AEs leading to study withdrawals. CONCLUSIONS: These data provide 
      evidence that MenACWY-CRM can be administered with typhoid Vi polysaccharide 
      vaccine and live attenuated YF vaccine without compromising antibody responses 
      stimulated by the individual vaccines. MenACWY-CRM can, therefore, be 
      incorporated into travelers' vaccination programs without necessitating an 
      additional clinic visit (NCT01466387).
CI  - (c) 2014 International Society of Travel Medicine.
FAU - Alberer, Martin
AU  - Alberer M
AD  - Department of Infectious Diseases and Tropical Medicine, University of Munich, 
      Munich, Germany.
FAU - Burchard, Gerd
AU  - Burchard G
FAU - Jelinek, Tomas
AU  - Jelinek T
FAU - Reisinger, Emil
AU  - Reisinger E
FAU - Beran, Jiri
AU  - Beran J
FAU - Hlavata, Lucie Cerna
AU  - Hlavata LC
FAU - Forleo-Neto, Eduardo
AU  - Forleo-Neto E
FAU - Dagnew, Alemnew F
AU  - Dagnew AF
FAU - Arora, Ashwani K
AU  - Arora AK
LA  - eng
SI  - ClinicalTrials.gov/NCT01466387
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20141013
PL  - England
TA  - J Travel Med
JT  - Journal of travel medicine
JID - 9434456
RN  - 0 (MenACWY-CRM vaccine)
RN  - 0 (Meningococcal Vaccines)
RN  - 0 (Polysaccharides, Bacterial)
RN  - 0 (Typhoid-Paratyphoid Vaccines)
RN  - 0 (Vaccines, Conjugate)
RN  - 0 (Vi polysaccharide vaccine, typhoid)
RN  - 0 (Yellow Fever Vaccine)
SB  - IM
MH  - Adult
MH  - Antibody Formation/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Immunization Schedule
MH  - Male
MH  - Meningococcal Infections/prevention & control
MH  - Meningococcal Vaccines/*administration & dosage/adverse effects/immunology
MH  - Middle Aged
MH  - Neutralization Tests
MH  - Polysaccharides, Bacterial/*administration & dosage/adverse effects/immunology
MH  - Serum Bactericidal Antibody Assay
MH  - Travel
MH  - Typhoid Fever/prevention & control
MH  - Typhoid-Paratyphoid Vaccines/*administration & dosage/adverse effects/immunology
MH  - Vaccination/methods
MH  - Vaccines, Conjugate/immunology
MH  - Yellow Fever/prevention & control
MH  - Yellow Fever Vaccine/*administration & dosage/adverse effects/immunology
MH  - Young Adult
EDAT- 2014/10/14 06:00
MHDA- 2015/09/15 06:00
CRDT- 2014/10/14 06:00
PHST- 2014/03/24 00:00 [received]
PHST- 2014/06/26 00:00 [revised]
PHST- 2014/07/21 00:00 [accepted]
PHST- 2014/10/14 06:00 [entrez]
PHST- 2014/10/14 06:00 [pubmed]
PHST- 2015/09/15 06:00 [medline]
AID - 10.1111/jtm.12164 [doi]
PST - ppublish
SO  - J Travel Med. 2015 Jan-Feb;22(1):48-56. doi: 10.1111/jtm.12164. Epub 2014 Oct 13.